Hypofractionated Radiotherapy for Small Cell Lung Cancer

Local control and overall survival rates associated with the standard chemotherapy and radiotherapy given for limited stage small cell lung cancer are poor and emerging evidence from several studies suggests that intensifying the radiotherapy dose given may further improve patient outcomes, but at the cost of increased radiotherapy side effects. This proposal aims to study a novel method of intensifying chest radiotherapy dose via increasing the daily radiotherapy dose which is directed at regions of visible disease only. This strategy allows for delivery of increased radiation doses without prolonging overall treatment time and allowing potential regrowth of cancer cells. We aim to determine the maximum radiation dose which can be safely given with chemotherapy for limited stage small cell lung cancer and study the effects this type of radiation regimen with chemotherapy has on patient side effects and quality of life. Results from this trial will contribute to the development of the ideal radiotherapy regimen for limited stage small cell lung cancer. Our results will add to the literature studying the effects dose-intense radiation strategies for lung cancer have on patient quality of life.

Inclusion criteria

• patients with histologically or cytologically proven newly diagnosed small cell lung cancer
• confirmation from the treating radiation oncologist that the patient has limited stage disease (i.e. disease that can be encompassed by radiotherapy portals without exposing patient to excessive risk of radiation lung injury)
• adequate pulmonary function tests (FEV-1 >1.0, DLCO >50%)
• patients of childbearing potential must practice adequate contraception
• age greater than 18 years
• Karnofsky performance status greater than 70
• adequate hematologic, hepatic and renal function: Hb>100g/L, WBC > 4.0x109/L, neutrophils > 1.0x109/L, platelets > 100,000x109/L, calculated GFR based on Cockcroft-Gault formula of >60mL/min (NOTE: for cisplatin, GFR must be above 60ml/min; if less than 60ml/min the patient can not receive cisplatin but could be considered for carboplatin)
• patients must sign a study specific informed consent form

Exclusion criteria

• patient who have undergone complete or subtotal tumour resection
• evidence of non-small cell histology
• pericardial or pleural effusion on radiologic investigations regardless of cytology
• patients cannot be treated with 3DCRT with adherence to the dose volume constraints
• prior or concurrent malignancy except non-melanomatous skin cancer unless disease-free for at least 5 years
• prior radiotherapy to the thorax or neck
• prior chemotherapy
• patients with myocardial infarction within the preceding 6 months or symptomatic heart disease, including angina, congestive heart failure, uncontrolled arrhythmias
• compromised lung function with inadequate pulmonary function tests (FEV-1<1.0, DLCO <50%)
• pregnancy (patients with childbearing potential must practice appropriate contraception)
• patients who have not had the pre-treatment evaluations outlined in the protocol